Annexon Inc. (ANNX)
2.29
0.05 (2.23%)
At close: Mar 28, 2025, 3:59 PM
2.25
-1.75%
Pre-market: Mar 31, 2025, 08:44 AM EDT
2.23% (1D)
| Bid | 2.2 |
| Market Cap | 251.24M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -102.58M |
| EPS (ttm) | -1.01 |
| PE Ratio (ttm) | -2.27 |
| Forward PE | -3.85 |
| Analyst | Buy |
| Ask | 2.3 |
| Volume | 704,566 |
| Avg. Volume (20D) | 1,425,346 |
| Open | 2.24 |
| Previous Close | 2.24 |
| Day's Range | 2.21 - 2.31 |
| 52-Week Range | 2.18 - 7.85 |
| Beta | 1.14 |
About ANNX
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/II...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 2020
Employees 100
Stock Exchange NASDAQ
Ticker Symbol ANNX
Website https://www.annexonbio.com
Analyst Forecast
According to 5 analyst ratings, the average rating for ANNX stock is "Buy." The 12-month stock price forecast is $14.5, which is an increase of 533.19% from the latest price.
Stock Forecasts3 months ago
+13.96%
Annexon shares are trading higher after the compan...
Unlock content with
Pro Subscription
6 months ago
+8.17%
Annexon shares are trading higher after the company announced it will present analyses of ANX007 from the completed Phase 2 ARCHER trial in geographic atrophy at the Retina Society's 57th annual scientific meeting being held September 11-15 in Lisbon, Portugal, and at the 24th annual Euretina Congress being held September 19–22 in Barcelona, Spain.
